236 related articles for article (PubMed ID: 27262694)
1. Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection.
Kaleko M; Bristol JA; Hubert S; Parsley T; Widmer G; Tzipori S; Subramanian P; Hasan N; Koski P; Kokai-Kun J; Sliman J; Jones A; Connelly S
Anaerobe; 2016 Oct; 41():58-67. PubMed ID: 27262694
[TBL] [Abstract][Full Text] [Related]
2. Nonclinical Safety Assessment of SYN-004: An Oral β-lactamase for the Protection of the Gut Microbiome From Disruption by Biliary-Excreted, Intravenously Administered Antibiotics.
Kokai-Kun JF; Bristol JA; Setser J; Schlosser M
Int J Toxicol; 2016 May; 35(3):309-16. PubMed ID: 26700136
[TBL] [Abstract][Full Text] [Related]
3. Tolerability and Pharmacokinetics of SYN-004, an Orally Administered β-Lactamase for the Prevention of Clostridium difficile-Associated Disease and Antibiotic-Associated Diarrhea, in Two Phase 1 Studies.
Roberts T; Kokai-Kun JF; Coughlin O; Lopez BV; Whalen H; Bristol JA; Hubert S; Longstreth J; Lasseter K; Sliman J
Clin Drug Investig; 2016 Sep; 36(9):725-734. PubMed ID: 27283946
[TBL] [Abstract][Full Text] [Related]
4. SYN-007, an Orally Administered Beta-Lactamase Enzyme, Protects the Gut Microbiome from Oral Amoxicillin/Clavulanate without Adversely Affecting Antibiotic Systemic Absorption in Dogs.
Connelly S; Fanelli B; Hasan NA; Colwell RR; Kaleko M
Microorganisms; 2020 Jan; 8(2):. PubMed ID: 31979034
[TBL] [Abstract][Full Text] [Related]
5. Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial.
Kokai-Kun JF; Roberts T; Coughlin O; Le C; Whalen H; Stevenson R; Wacher VJ; Sliman J
Lancet Infect Dis; 2019 May; 19(5):487-496. PubMed ID: 30885591
[TBL] [Abstract][Full Text] [Related]
6. Formulation development of SYN-004 (ribaxamase) oral solid dosage form, a β-lactamase to prevent intravenous antibiotic-associated dysbiosis of the colon.
Bristol A; Hubert S; Hofmann F; Baer H
Int J Pharm; 2017 Dec; 534(1-2):25-34. PubMed ID: 28986322
[TBL] [Abstract][Full Text] [Related]
7. The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies.
Kokai-Kun JF; Roberts T; Coughlin O; Sicard E; Rufiange M; Fedorak R; Carter C; Adams MH; Longstreth J; Whalen H; Sliman J
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052855
[TBL] [Abstract][Full Text] [Related]
8. Oral Beta-Lactamase Protects the Canine Gut Microbiome from Oral Amoxicillin-Mediated Damage.
Connelly S; Fanelli B; Hasan NA; Colwell RR; Kaleko M
Microorganisms; 2019 May; 7(5):. PubMed ID: 31137766
[TBL] [Abstract][Full Text] [Related]
9. Oral Metallo-Beta-Lactamase Protects the Gut Microbiome From Carbapenem-Mediated Damage and Reduces Propagation of Antibiotic Resistance in Pigs.
Connelly S; Fanelli B; Hasan NA; Colwell RR; Kaleko M
Front Microbiol; 2019; 10():101. PubMed ID: 30804903
[TBL] [Abstract][Full Text] [Related]
10. Low dose oral beta-lactamase protects the gut microbiome from oral beta-lactam-mediated damage in dogs.
Connelly S; Fanelli B; Hasan NA; Colwell RR; Kaleko M
AIMS Public Health; 2019; 6(4):477-487. PubMed ID: 31909068
[TBL] [Abstract][Full Text] [Related]
11. Orally administered beta-lactamase enzymes represent a novel strategy to prevent colonization by Clostridium difficile.
Stiefel U; Nerandzic MM; Koski P; Donskey CJ
J Antimicrob Chemother; 2008 Nov; 62(5):1105-8. PubMed ID: 18693236
[TBL] [Abstract][Full Text] [Related]
12. SYN-004 (ribaxamase), an oral beta-lactamase, mitigates antibiotic-mediated dysbiosis in a porcine gut microbiome model.
Connelly S; Bristol JA; Hubert S; Subramanian P; Hasan NA; Colwell RR; Kaleko M
J Appl Microbiol; 2017 Jul; 123(1):66-79. PubMed ID: 28245091
[TBL] [Abstract][Full Text] [Related]
13. Identification, Characterization, and Formulation of a Novel Carbapenemase Intended to Prevent Antibiotic-Mediated Gut Dysbiosis.
Connelly S; Parsley T; Ge H; Kaleko M
Microorganisms; 2019 Jan; 7(1):. PubMed ID: 30654495
[TBL] [Abstract][Full Text] [Related]
14. Distinct consequences of amoxicillin and ertapenem exposure in the porcine gut microbiome.
Connelly S; Subramanian P; Hasan NA; Colwell RR; Kaleko M
Anaerobe; 2018 Oct; 53():82-93. PubMed ID: 29689301
[TBL] [Abstract][Full Text] [Related]
15. Use your antibiotics wisely. Consequences to the intestinal microbiome.
Cervantes J
FEMS Microbiol Lett; 2016 May; 363(10):. PubMed ID: 27044298
[TBL] [Abstract][Full Text] [Related]
16. IPSAT P1A, a class A beta-lactamase therapy for the prevention of penicillin-induced disruption to the intestinal microflora.
Pitout JD
Curr Opin Investig Drugs; 2009 Aug; 10(8):838-44. PubMed ID: 19649928
[TBL] [Abstract][Full Text] [Related]
17. [Oncologic aspects of Clostridium difficile].
Telekes A
Orv Hetil; 2016 Jul; 157(28):1110-6. PubMed ID: 27397423
[TBL] [Abstract][Full Text] [Related]
18. P1A recombinant beta-lactamase prevents emergence of antimicrobial resistance in gut microflora of healthy subjects during intravenous administration of ampicillin.
Tarkkanen AM; Heinonen T; Jõgi R; Mentula S; van der Rest ME; Donskey CJ; Kemppainen T; Gurbanov K; Nord CE
Antimicrob Agents Chemother; 2009 Jun; 53(6):2455-62. PubMed ID: 19307374
[TBL] [Abstract][Full Text] [Related]
19. Impact of microbial derived secondary bile acids on colonization resistance against Clostridium difficile in the gastrointestinal tract.
Winston JA; Theriot CM
Anaerobe; 2016 Oct; 41():44-50. PubMed ID: 27163871
[TBL] [Abstract][Full Text] [Related]
20. Of stewardship, motherhood and apple pie.
Livermore DM
Int J Antimicrob Agents; 2014 Apr; 43(4):319-22. PubMed ID: 24630303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]